Eyenovia

DelveInsight's 'Mydriasis Pipeline Insight, 2024' report details the global Mydriasis pipeline, featuring 3+ key companies developing 3+ therapies. Insights include clinical trials, mechanism of action, route of administration, and emerging therapies like RYZUMVI, MYDCOMBI, and OMIDRIA. The report covers pre-clinical to marketed phases, highlighting active and inactive projects, collaborations, and market dynamics.

Eyenovia's stock price dropped by over two-thirds after its Phase III study for myopia treatment failed to meet primary endpoint, leading to study termination and strategic option evaluation.

CareMax files for Chapter 11 bankruptcy in Texas with $693 million in debts. Bangladesh faces a severe dengue crisis with over 400 deaths. California reports its first clade I mpox case, while Oregon records its first human bird flu case. The UK combats bird flu with poultry culling and protection zones. Eyenovia halts an eye drug study and cuts staff, contrasting with Syndax Pharmaceuticals' FDA approval for a blood cancer drug.

Investors react negatively to Trump's nomination of RFK Jr. for HHS, causing COVID-19 vaccine stocks to tumble, with Moderna and BioNTech seeing significant losses. RFK Jr.'s criticism of COVID-19 vaccines and potential impact on vaccine policy contribute to investor concerns. Psychedelic drug companies, however, see stock increases due to RFK's support for the field.

Eyenovia, Inc. announced that CHAPERONE, its Phase 3 study evaluating a low-dose atropine treatment for pediatric progressive myopia, did not meet its primary endpoint. The independent Data Review Committee found no significant difference in myopia progression between treatment arms and placebo. Eyenovia plans to discontinue the study, review the data, and evaluate next steps.

Eyenovia terminates Phase III trial of drug-device combo for pediatric myopia, citing lack of success, and considers all strategic options.

Eyenovia's stock dropped to under 10 cents after discontinuing a Phase III pediatric myopia study, as its drug-device combo MicroPine failed to meet primary endpoints. The company has two marketed products, including clobetasol propionate eye drops for post-operative inflammation, and MydCombi for mydriasis.